PWE-025 Assessing the Percent of Days Linaclotide Improved Abdominal Symptoms and Stool Frequency in Patients with Irritable Bowel Syndrome with Constipation (IBS-C): Pooled Analysis of 2 Phase 3 Trials

S S Rao,M Currie,X Cao,S J Shiff,L Chang,X Hao,H Schneier,J Johnston,B Lavins

doi:10.1136/gutjnl-2013-304907.314

PWE-025 Assessing the Percent of Days Linaclotide Improved Abdominal Symptoms and Stool Frequency in Patients with Irritable Bowel Syndrome with Constipation (IBS-C): Pooled Analysis of 2 Phase 3 Trials

S S Rao, M Currie + Show 7 more

Open Access

https://doi.org/10.1136/gutjnl-2013-304907.314

Copy DOI

Journal: Gut

Publication Date: Jun 1, 2013

Affiliation: Ironwood Pharmaceuticals (United States), University of California, Los Angeles

#Ironwood Pharmaceuticals #Irritable Bowel Syndrome With Constipation + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

IntroductionLinaclotide (LIN), a minimally absorbed guanylate cyclase C agonist (GCCA), improved abdominal symptoms and bowel movement (BM) frequency in patients (pts) with IBS-C in 2 Phase 3 trials. This post-hoc...

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Gut

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.